spacer
home > ebr > spring 2007 > environmental exposure
PUBLICATIONS
European Biopharmaceutical Review

Environmental Exposure

Brigitte van Noorloos at NOTOX examines the impact of pharmaceuticals on the environment, and the step-by-step approach that offers the industry clear guidance

The medicines that we take have gone through at least 10 years of testing so that their safety for humans can be guaranteed. However, we are not the only ones that may be exposed to these drugs. Human drugs may also affect animals, plants and bacteria as they can enter the environment via human excreta or by the disposal of expired medicines via the sewer. This has been recognised by the EU and, from December 2006, it is not only the efficacy of pharmaceuticals and their side effects that need to be evaluated, but also the environmental impact of the active ingredients. This article provides an outline of the EUEMEA guideline’s step-by-step approach.

BACKGROUND

In the last 15 to 20 years there have been several reports of pharmaceuticals affecting the environment: human and veterinary drugs have been detected in river water and even drinking water (1,2). Although reported levels are very low, some negative effects were observed, a noteworthy example being hormone disruption in fish due to the presence of estrogens in the environment.

In the case of use, patients will usually excrete a drug or its metabolites, which then pass to a sewage treatment plant. There, they may be partially degraded, they may be adsorbed to the sludge, or they may remain in the effluent. After processing at the sewage treatment plant, the sludge is usually incinerated, but it may also be spread on the land, and then leach into the soil and eventually into the groundwater. In terms of disposal, depending on the route (drain, household or industrial waste), pharmaceuticals may enter the groundwater and surface water via a sewage treatment plant or by leaching from a landfill site.

Although pharmaceuticals and their metabolites in excreta will be diluted before entering the sewage treatment plant, and even though leaching from a landfill site may be limited, it should be kept in mind that drugs are usually relatively stable – after all, they were developed to remain intact in the human body, at least for a certain period. Furthermore, as they were developed with the objective to cause a physiological effect in humans, other organisms may be sensitive to them as well.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Brigitte van Noorloos graduated with an MSc in Chemistry from the University of Nijmegen, the Netherlands. Since 2000, she has supervised environmental fate and metabolism studies at NOTOX in ‘s-Hertogenbosch, the Netherlands. Initially, the work mainly concerned agrochemicals and industrial chemicals, but now pharmaceuticals have also become a major area of environmental testing. Brigitte was also involved in dossier preparation of high production volume chemicals and the risk evaluation of agrochemicals for the Dutch Board for the Authorisation of Pesticides (CTB).
spacer
Brigitte van Noorloos
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement